Tempus AI, Inc. Class A Common Stock
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.87%.
Did TEM Beat Earnings? Q1 2025 Results
Tempus AI delivered a notably strong first quarter for 2025, beating Wall Street expectations on both the top and bottom lines as its expanding genomics business and high-margin data services drove momentum across the organization. The company posted a Non-GAAP loss of $0.24 per share, ahead of the $0.27 consensus estimate by 10.21%, while revenue climbed 75.4% year-over-year to $255.74 million, topping forecasts by 3.07%. The primary engine behind that growth was the February completion of the Ambry Genetics acquisition, which propelled Genomics segment revenue up 88.9% and contributed $63.50 million in hereditary testing revenue alone. Gross margin expanded meaningfully to 60.7% from 53.3% a year ago, reflecting improving operating leverage across both business segments. Investors <a href="https://247wallst.com/investing/2025/11/04/live-will-tempus-ai-move-higher-after-earnings/">watching Tempus closely</a> also got a forward-looking boost, as the company raised full-year 2025 revenue guidance to approximately $1.25 billion — representing roughly 80% annual growth — and now projects positive Adjusted EBITDA of $5 million for the year, a roughly $110 million improvement over 2024.
- Genomics revenue grew 88.9% YoY driven by Ambry Genetics acquisition and organic oncology testing growth
- Oncology testing volume growth of approximately 20%
- Hereditary testing unit growth of approximately 23%
- Insights (data licensing) revenue grew 58.0% YoY
- Gross margin improvement in both Genomics (56.3% vs 48.5%) and Data and services (74.6% vs 64.7%)
- Significant operating leverage with Adjusted EBITDA improving $27.8 million YoY
“The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage. Our strategic investments in AI have us uniquely positioned to advance what is possible in diagnostics and drug development, as evidenced by our announcement to build the largest foundation model in oncology with AstraZeneca and Pathos. We believe this is just the beginning as more and more healthcare providers and life science companies embrace AI.”
Tempus AI CEO, on the earnings call
Forward Guidance & Outlook
Tempus raised full-year 2025 revenue guidance to approximately $1.25 billion for the consolidated Tempus and Ambry Genetics business, representing approximately 80% annual growth year-over-year. The company now expects positive Adjusted EBITDA of $5 million for full year 2025, an improvement of approximately $110 million over 2024.
TEM YoY Financials
TEM Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.